Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 13.04 AUD -0.91% Market Closed
Market Cap: 652.8m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Relative Value

The Relative Value of one CUV stock under the Base Case scenario is 17.68 AUD. Compared to the current market price of 13.04 AUD, Clinuvel Pharmaceuticals Ltd is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CUV Relative Value
Base Case
17.68 AUD
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
49
Median 3Y
12.4
Median 5Y
15.5
Industry
7.7
Forward
6.7
vs History
98
vs Industry
7
Median 3Y
33.9
Median 5Y
45.2
Industry
22.7
Forward
18
vs History
92
vs Industry
9
Median 3Y
23
Median 5Y
29.8
Industry
21.6
vs History
85
vs Industry
7
Median 3Y
24
Median 5Y
30.2
Industry
25.2
vs History
98
vs Industry
21
Median 3Y
6.4
Median 5Y
8.3
Industry
2.5
vs History
98
vs Industry
48
Median 3Y
10.5
Median 5Y
13.8
Industry
7.7
Forward
4.8
vs History
84
vs Industry
48
Median 3Y
10.3
Median 5Y
11.6
Industry
9
vs History
98
vs Industry
9
Median 3Y
17.6
Median 5Y
23.6
Industry
4.2
Forward
10.2
vs History
98
vs Industry
8
Median 3Y
17.6
Median 5Y
23.6
Industry
4.1
Forward
10.6
vs History
95
vs Industry
10
Median 3Y
19.6
Median 5Y
26.2
Industry
5.7
vs History
92
vs Industry
8
Median 3Y
20.1
Median 5Y
26.3
Industry
3.6
vs History
98
vs Industry
14
Median 3Y
40.5
Median 5Y
61
Industry
4.6

Multiples Across Competitors

CUV Competitors Multiples
Clinuvel Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
653m AUD 6.8 18.3 8.2 8.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average P/E: 176.6
18.3
46%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBITDA: 15.9
8.2
17%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBIT: 20.5
8.2
25%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top